0.97
price down icon2.74%   -0.0396
after-market Handel nachbörslich: 1.01 0.04 +4.12%
loading

Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten

pulisher
May 30, 2025

Estrella Immunopharma’s (ESLA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World

May 30, 2025
pulisher
May 29, 2025

Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial - Yahoo

May 29, 2025
pulisher
May 29, 2025

ESLA Stock Rating and Price Target Maintained by D. Boral Capita - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma, Inc. Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma Advances STARLIGHT-1 Clinical Trial - TipRanks

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas - BioSpace

May 29, 2025
pulisher
May 29, 2025

ESLA Stock Rating and Price Target Maintained by D. Boral Capital | ESLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma (ESLA) Advances in Phase I/II STARLIGHT-1 Trial | ESLA Stock News - GuruFocus

May 29, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Acquires 16,862 Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) - Defense World

May 05, 2025
pulisher
Apr 24, 2025

ESLA Stock: A Voyage Through Estrella Immunopharma Inc’s Finances - investchronicle.com

Apr 24, 2025
pulisher
Apr 24, 2025

A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com

Apr 24, 2025
pulisher
Mar 05, 2025

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners - BioSpace

Mar 05, 2025
pulisher
Feb 22, 2025

Estrella Immunopharma completes first dose cohort in STARLIGHT trial - Yahoo Finance

Feb 22, 2025
pulisher
Feb 21, 2025

Sector Update: Health Care -February 21, 2025 at 03:42 pm EST - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose Cohort - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort - The Bakersfield Californian

Feb 21, 2025
pulisher
Feb 20, 2025

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital - 01net

Feb 20, 2025
pulisher
Feb 19, 2025

Estrella Immunopharma (NASDAQ:ESLA) Now Covered by Analysts at D. Boral Capital - Defense World

Feb 19, 2025
pulisher
Feb 18, 2025

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Feb 18, 2025
pulisher
Dec 16, 2024

Estrella Immunopharma regains Nasdaq compliance - Investing.com

Dec 16, 2024
pulisher
Dec 13, 2024

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Quotes, Forecast and News Summary - Benzinga

Dec 13, 2024
pulisher
Dec 12, 2024

vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga

Dec 12, 2024
pulisher
Dec 08, 2024

Estrella Immunopharma extends stock sale agreement with White Lion By Investing.com - Investing.com Canada

Dec 08, 2024
pulisher
Nov 25, 2024

Estrella Immunopharma faces Nasdaq delisting over equity shortfall - Investing.com India

Nov 25, 2024
pulisher
Nov 14, 2024

Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider - Simply Wall St

Nov 14, 2024
pulisher
Nov 11, 2024

Eureka Therapeutics Tackling Advanced Hepatocellular Carcinoma With T-Cell Therapy ECT204 in Phase 1/2 ARYA-3 Clinical Trial - CGTLive™

Nov 11, 2024
pulisher
Nov 07, 2024

Estrella Immunopharma Appoints Dr. Cheng Liu as CEO - TipRanks

Nov 07, 2024
pulisher
Oct 31, 2024

Tesla stock hits 52-week low at $0.75 amid market challenges - Investing.com

Oct 31, 2024
pulisher
Oct 09, 2024

Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™

Oct 09, 2024
pulisher
Oct 03, 2024

First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive®

Oct 03, 2024
pulisher
Sep 27, 2024

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells - BioSpace

Sep 27, 2024
pulisher
Aug 14, 2024

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member - Business Wire

Aug 14, 2024
pulisher
Aug 06, 2024

Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas Doses First Patient - CGTLive®

Aug 06, 2024
pulisher
Jul 26, 2024

Wall Street today: US stocks trade higher after promising inflation data raises Fed rate cut bets; 3M Co. gains 18.99% - Mint

Jul 26, 2024
pulisher
Jul 06, 2024

OS Therapies (AMEX:OSTX) Stock Quotes, Forecast and News Summary - Benzinga

Jul 06, 2024
pulisher
Jul 02, 2024

Estrella Immunopharma streamlines operations with subsidiary merger - Investing.com India

Jul 02, 2024
pulisher
Apr 01, 2024

Laura Franco - Mintz

Apr 01, 2024
pulisher
Jan 18, 2024

Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances - InvestorPlace

Jan 18, 2024
pulisher
Dec 18, 2023

Excision Seeks to Suppress HIV Viral Replication With EBT-101 CRISPR Gene Therapy - CGTLive™

Dec 18, 2023
pulisher
Dec 04, 2023

Direct Biologics’ Phase 1 Clinical Trial Seeks to Treat Crohn Disease With Extracellular Vesicles - CGTLive™

Dec 04, 2023
pulisher
Nov 06, 2023

Tenaya's Phase 1b MyPeak-1 Trial is Testing the Waters in Gene Therapy for Hypertrophic Cardiomyopathy - CGTLive™

Nov 06, 2023
pulisher
Oct 24, 2023

ESLAEstrella Immunopharma Latest Stock News & Market Updates - StockTitan

Oct 24, 2023
pulisher
Oct 02, 2023

ESLA Stock Price and Chart — NASDAQ:ESLA - TradingView

Oct 02, 2023
pulisher
Sep 19, 2023

Estrella Immunopharma nears completion of SPAC listing - Bamboo Works

Sep 19, 2023
pulisher
Sep 13, 2023

Calidi Biotherapeutics (AMEX:CLDI) Stock Quotes, Forecast and News Summary - Benzinga

Sep 13, 2023
pulisher
Oct 03, 2022

Estrella and TradeUP merge to become publicly traded company - Labiotech.eu

Oct 03, 2022
pulisher
Aug 26, 2022

Manufacturing Stocks Investing - MarketBeat

Aug 26, 2022
pulisher
May 06, 2022

PepGen (NASDAQ:PEPG) Stock Quotes, Forecast and News Summary - Benzinga

May 06, 2022
pulisher
Nov 04, 2021

TradeUP Acquisition (UPTD) Stock Price, News & Analysis - MarketBeat

Nov 04, 2021
pulisher
Aug 27, 2021

Aadi Bioscience (NASDAQ:AADI) Stock Quotes, Forecast and News Summary - Benzinga

Aug 27, 2021
pulisher
Jul 21, 2021

Immuneering (NASDAQ:IMRX) Stock Quotes, Forecast and News Summary - Benzinga

Jul 21, 2021
pulisher
Jun 28, 2021

Tempest Therapeutics (NASDAQ:TPST) Stock Quotes, Forecast and News Summary - Benzinga

Jun 28, 2021
pulisher
Apr 06, 2021

Achilles Therapeutics (NASDAQ:ACHL) Stock Quotes, Forecast and News Summary - Benzinga

Apr 06, 2021
pulisher
Jan 12, 2021

Lantern Pharma (NASDAQ:LTRN) Stock Quotes, Forecast and News Summary - Benzinga

Jan 12, 2021
pulisher
Jan 07, 2021

OncoCyte (NASDAQ:OCX) Stock Quotes, Forecast and News Summary - Benzinga

Jan 07, 2021
$1.15
price up icon 6.29%
$31.19
price up icon 3.45%
$584.61
price up icon 2.01%
$306.09
price up icon 0.42%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.09%
Kapitalisierung:     |  Volumen (24h):